Clinical Trials

Is your family from India, Pakistan, Bangladesh, Nepal, or Sri Lanka? If so, you may be able to participate in a clinical study looking at cardiovascular disease, such as heart disease and stroke among people of South Asian descent. Participants must be between 40 and 84 years old and have no history of heart attack or stroke, heart failure, angina, or atrial fibrillation. This study is taking place in San Francisco, California, Chicago, Illinois, and New York City, New York.

The goal of this work is to develop and test a noninvasive ultrasound-based imaging technology to better identify patients at high risk of stroke so that appropriate and timely intervention may be administered to prevent it.

Are you at least 40 years old and living with HIV? In this study, researchers are looking at how effective educational text messages are in reducing cardiovascular risk among persons living with HIV. You may be able to participate if you do not currently have atherosclerosis, which is the buildup of fats and cholesterol on your artery walls. The study is taking place in San Francisco, California.

Are you an adult with carotid artery stenosis (CAS)? Researchers in this study want to learn more about the plaque that causes atherosclerosis in patients with carotid artery stenosis. To be in the study, you must be at least 18 years old and will undergo a carotid positron emission tomography (PET)/magnetic resonance imaging exam so researchers can lean more on the new PET imaging approach for risk prediction in these patients. The study is taking place Saint Louis, Missouri, and in Los Angeles, California.

Are you planning to have coronary artery bypass grafting (CABG) surgery to treat your heart disease? This study aims to use computed tomography (CT) imaging to help doctors and their patients make better decisions about heart surgery. To participate in this study, you must be at least 40 years old and be scheduled for a CABG. This study is located in Palo Alto and San Diego, California

DIVA is a pragmatic randomized clinical trial (RCT) to determine: among (P) preterm infants born 24-27 6/7 weeks gestation undergoing extubation from mechanical ventilation, whether (I) Non-invasive neurally adjusted ventilatory assist (NIV-NAVA) (C) compared with Non-synchronized nasal intermittent positive pressure ventilation (NS-NIPPV), will reduce the incidence of (O) extubation failure within (T) 5 days (120 hours) of extubation.

This is an observational - data and specimen collection study. There have been increasing reports of vaping-induced lung injury, including severe lung injury and rare cases of death. The mechanism by which vaping contributes to lung injury in susceptible persons is unknown, as is impact on chronic lung disease. The investigators aim to identify individuals with chronic electronic nicotine delivery device (ENDD) exposure and matched controls within our ongoing cohort of HIV+ and HIV-uninfected individuals, collect PFT data, bank respiratory and stool samples and collect clinical data for studies of clinical risk, inflammation, biomarkers, and the microbiome in the identification and modification of risk of progression to lung injury or chronic pulmonary disease.

The purpose of this study is to see if adding a drug called Regadenoson to the EVLP circulation reservoir during perfusion of marginal donor lungs will help increase the likelihood that the donor lungs will become usable for transplantation.

The purpose of this study is to evaluate whether biomarkers of lung injury and remodeling are responsive to effective continuous positive airway pressure (CPAP) treatment in adults with idiopathic pulmonary fibrosis (IPF) and moderate-to-severe obstructive sleep apnea (OSA).

Are you an adult who has idiopathic pulmonary fibrosis or an advanced lung cancer? This study aims to see whether a new imaging dye for positron emission tomography (PET) is effective at looking at fibrosis in lung cancer and idiopathic pulmonary fibrosis (IPF). Participants will be given the imaging dye and then receive a PET scan. To participate in this study, you must either be between 18 and 80 years old and have lung cancer or be a healthy volunteer or be between 50 and 80 years old and have IPF. This study is located in Boston, Massachusetts.